Search
Asthma Paid Clinical Trials in Pennsylvania
A listing of 22 Asthma clinical trials in Pennsylvania actively recruiting volunteers for paid trials and research studies in various therapeutic areas.
13 - 22 of 22
Match to Clinical Trials
Access to cutting-edge treatments
Latest clinical trials
Find trials in your area
Search by Name
Filter by Condition
Asthma
Filter by Age
Filter by Type
Gender
Type of Study
Clinical Trial Phase
The state of Pennsylvania currently has 22 active clinical trials seeking participants for Asthma research studies. These trials are conducted in various cities, including Philadelphia, Pittsburgh, Hershey and Allentown.
Featured Trial
Chronic Cough Study
Recruiting
Are you tired of living with chronic cough? The ASPIRE Study is now looking to enroll people from all backgrounds to help research potential new treatment options for chronic cough. You are under no obligation to take part and health insurance is not required. Find out more today! We’d love to hear from you.
Conditions:
Chronic Cough
Refractory or Unexplained Chronic Cough
Cough
Asthma
Allergic Asthma
Featured Trial
A Study on the Efficacy, Safety, and Tolerability of an Investigational Drug in Participants with Severe Eosinophilic Asthma
Recruiting
The primary aim of this clinical trial is to study the potential effectiveness of an investigational drug in treating severe eosinophilic asthma, characterized by persistent symptoms and frequent flare-ups despite regular asthma medication. Secondary goals of this study include evaluating the safety and tolerability aspects of the investigational drug. To maintain objectivity, participants are randomly assigned into groups, receiving either the actual drug or a placebo. The outcome of this research will be instrumental in determining if the investigational drug stands as a possible treatment for those grappling with severe eosinophilic asthma. If you are interested in applying for this study, initiating contact will lead to direct engagement from the research site. They will provide more information on the study and answer any questions related to participation requirements, the potential risks and benefits, and any compensation on offer.
Conditions:
Asthma
All Conditions
Featured Trial
Studying an Investigational Medication in Adults with Eczema
Recruiting
The main objectives of this study are to evaluate the safety and effectiveness of an investigational medication in adults with moderate to severe atopic dermatitis, commonly known as eczema. The study aims to understand how different dosages of the investigational medication affect eczema flare ups. Participants will be randomly assigned to receive various dosages of the investigational medication or a placebo. Should you express interest, you will be contacted directly by the research site, who will provide further details and answer any questions you may have about study requirements, risks/benefits, and any compensation.
Conditions:
All Conditions
Dermatology
Eczema (Atopic dermatitis)
Featured Trial
High Triglyceride Clinical Research Study
Recruiting
Living with high triglycerides? See if our clinical study is right for you.
Don’t let financial stress hold you back. All clinical study-related assessments, care, and the investigational study drug are available at no cost. You could also be eligible for compensation for travel.
Don’t let financial stress hold you back. All clinical study-related assessments, care, and the investigational study drug are available at no cost. You could also be eligible for compensation for travel.
Conditions:
High Triglycerides
High Triglyceride Level
Hypertriglyceridemia
Elevated Triglycerides
Triglycerides High
Featured Trial
Lose Weight with GLP-1 Medications
Recruiting
Policy Lab has partnered with CareGLP to offer trusted access to GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
Conditions:
Overweight
Overweight and Obesity
Obesity
Weight Loss
Morbid Obesity
Featured Trial
Paid Clinical Studies Nationwide
Recruiting
Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.
Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Adult Patients With Uncontrolled Moderate to Severe Asthma
Recruiting
This is an interventional, randomized, parallel group, treatment, Phase 3b/4, double blind, 2-arm study to assess the effect of dupilumab compared to standard of care therapy on preventing or slowing the rate of lung function decline in adult patients with uncontrolled moderate to severe asthma.
The estimated duration is 4±1 weeks of screening and run-in period, followed by a 3-year double blinded treatment period. There will be a post-treatment follow-up (FU) period up to 12 weeks.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/06/2025
Locations: St. Luke's University Hospital- Site Number : 8400099, Bethlehem, Pennsylvania +2 locations
Conditions: Asthma
A Phase 2, Dose Ranging Study Assessing Rocatinlimab in Moderate-to-severe Asthma
Recruiting
The primary objective of this study is to describe the efficacy of rocatinlimab in reducing asthma exacerbations.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
03/06/2025
Locations: Clinical Research Associates of Central Pennsylvania, DuBois, Pennsylvania +1 locations
Conditions: Asthma
REIMAGINE - Real World EvaluatIon of Mepolizumab in Severe Asthma achievinG on Treatment clinIcal remissioN, a prospEctive Study
Recruiting
This is a prospective, real-world, single arm, global, multi-centre study to evaluate the effect of timely treatment with mepolizumab (NUCALA) to achieve clinical remission in adult participants with severe asthma with an eosinophilic phenotype (SA-EP).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/25/2025
Locations: GSK Investigational Site, Philadelphia, Pennsylvania +1 locations
Conditions: Asthma
A Study to Assess the Effect of Dexpramipexole in Adolescents and Adults With Severe Eosinophilic Asthma (EXHALE-3)
Recruiting
The objective of this clinical study is to investigate the safety, tolerability, and efficacy of dexpramipexole in participants with inadequately controlled severe eosinophilic asthma.
Gender:
ALL
Ages:
Between 12 years and 99 years
Trial Updated:
02/24/2025
Locations: Research Site US-30001-327, Philadelphia, Pennsylvania
Dose Ranging Study of Lunsekimig Compared With Placebo-control in Adult Participants With Moderate-to-severe Asthma
Recruiting
This is a Phase 2b, global, multicenter, randomized, double-blind, placebo-controlled, parallel group, dose ranging study to assess the efficacy, safety, and tolerability of add-on therapy with SC lunsekimig in adult participants aged 18 to 80 years, (inclusive) with moderate-to-severe asthma.
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
02/16/2025
Locations: Clinical Research Associates of Central PA - Dubois- Site Number : 8400069, DuBois, Pennsylvania +2 locations
Conditions: Asthma
Benralizumab Airway Remodeling Study in Severe Eosinophilic Asthmatics
Recruiting
The purpose of the study is to evaluate effect of benralizumab on structural and lung function changes in severe eosinophilic asthmatics.
Changes will be assessed over 48 week treatment period in patients with persistent symptoms despite standard therapy of inhaled corticosteroids (ICS) plus long acting B2-agonist (LABA) with or without additional controller medication.
Patients who complete treatment will enter 4 weeks follow-up period.
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
02/12/2025
Locations: Research Site, Philadelphia, Pennsylvania +3 locations
Conditions: Asthma
Evaluating the Efficacy and Safety of PT027 Compared With PT007 Administered As Needed in Participants 12 to < 18 Years of Age With Asthma
Recruiting
The purpose of this study is to compare the effect of budesonide/albuterol metered-dose inhaler (BDA MDI) with albuterol sulfate metered-dose inhaler (AS MDI), both administered as needed, on the annualized rate of severe asthma exacerbations in adolescents with a documented clinical diagnosis of asthma and at least one severe exacerbation in the prior year.
Gender:
ALL
Ages:
Between 12 years and 17 years
Trial Updated:
12/19/2024
Locations: Research Site, Pittsburgh, Pennsylvania
Conditions: Asthma
Measuring the Effect of Dupilumab Treatment on Mucociliary Clearance (MCC) in Subjects With Moderate to Severe Asthma
Recruiting
Single center, randomized, placebo- controlled study to assess change in mucociliary clearance of moderate to severe asthma patients after treatment with dupilumab or placebo.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/10/2024
Locations: The University of Pittsburgh Asthma Institute at UPMC, Pittsburgh, Pennsylvania
Conditions: Asthma
Investigating Dupilumab's Effect in Asthma by Genotype
Recruiting
The Goal of this study is to investigate if individuals ages 12 years and older, carrying the IL-4RαR576 gene variant, will have a greater response to therapy acting directly on the anti-IL-4R. This will be conducted by examining the effect of a 48 week therapy with dupilumab on the rate of asthma exacerbations.
Gender:
ALL
Ages:
12 years and above
Trial Updated:
11/22/2024
Locations: University of Pennsylvania, Philadelphia, Pennsylvania
Conditions: Asthma
Acoustic Waveform Respiratory Evaluation
Recruiting
The study will evaluate the feasibility of using smartphone speakers and microphones to evaluate the caliber of the airways, detect airway obstruction, aid in airway disease diagnosis, and identify disease exacerbations.
Gender:
ALL
Ages:
Between 8 years and 65 years
Trial Updated:
09/11/2024
Locations: University of Pittsburgh, Pittsburgh, Pennsylvania
Conditions: Asthma, COPD, Cystic Fibrosis, Ciliary Motility Disorders, Bronchiectasis, Airway Malacia, Healthy Control
13 - 22 of 22